A new drug lowers blood sugar in patients with type-2 diabetes, according to a new study.
Researchers found Dapagliflozin prevented the reabsorption of glucose by the kidneys and increased the amount of sugar released in the urine.
The drug, which works independently of insulin, could help those who have inadequate blood sugar control with first line drug metformin, the study found.
Researchers believe it could also help those with early and late stage diabetes.
The findings are reported in an article in this week’s American Diabetes Association meeting Special Issue of The Lancet, written by Professor Clifford Bailey, Aston University, Birmingham, UK, and colleagues.
Since many complications of diabetes are related to high concentrations of blood glucose, directly lowering blood glucose is a legitimate target for new drugs for diabetes.
In this study, the authors assessed the efficacy and safety of dapagliflozin in patients not managing to control their blood sugar with the first-line treatment of metformin.
The phase 3 randomised controlled trial assessed 546 adult patients with diabetes, who were receiving daily metformin, yet had inadequate blood sugar control.